Vinge has advised Industrifonden in connection with its investment in MinervaX.
MinervaX has developed a vaccine against streptococcus and in connection with the financing round has procured a total of MEUR 47.4 from a syndicate consisting of Industrifonden, Sanofi Ventures, Wellington Partners and Adjuvant Capital.
Vinge’s team primarily consisted of Johan Larsson, Sara Strandberg and Stojan Arnerstål.